AMLXAMLXHealthcare · Drug Manufacturers - Specialty & Generic

AMLX Stock Forecast: Amylyx Pharmaceuticals, Inc. Price Predictions for 2026-2027

Last close, 18 Nov 2026
$27
−3.27% on the day

The 11 Wall Street analysts covering Amylyx Pharmaceuticals, Inc. hold a median 12-month price target of $40 — +50.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 60 of 100 as at 17 Nov 2026 — in the upper half.

Market cap
$3.6B
Ticker Nerd rank
60/ 100
Median analyst target
$40
Analysts covering
11
Revenue$0.0
Operating income−$45.7M
Net income−$43.4M
Free cash flow−$31.5M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−16.3%
1M
+1.1%
YTD
+120.4%
1Y
+90.8%
From 52W high
−32.9%
From 52W low
+133.9%
$11
$40
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

AMLX stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Amylyx Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 17 Nov 2026
60/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
94
Value
77
Volatility
63
Growth
63
Accruals
50
Revisions
49
Quality
49
Issuance
38
Size
28

Momentum (94): The shares have been drifting up relative to others.

Issuance (38): The company has been issuing shares or taking on financing, diluting existing holders.

Size (28): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

AMLX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on AMLX, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$10$20$30$40$50$60Jan 26Apr 26Jul 26Oct 26AMLXHigh $57Median $40Low $25

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says11 analysts
10 Buy1 Hold0 Sell
Low $25Median $40High $57

The green dot is the last close — the median target sits +50.3% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 11 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
10 Nov 2026MizuhoMaintainsOutperform$38 → $39
15 Oct 2026CitigroupMaintainsBuy—
15 Oct 2026CitigroupMaintainsBuy$32 → $39
27 Aug 2026GuggenheimMaintainsBuy$55 → $57
27 Aug 2026GuggenheimMaintainsBuy—
19 Aug 2026BairdMaintainsOutperform—
19 Aug 2026BairdMaintainsOutperform$28 → $52
19 Aug 2026GuggenheimMaintainsBuy$40 → $55
19 Aug 2026GuggenheimMaintainsBuy—
19 Aug 2026MizuhoMaintainsOutperform—
19 Aug 2026MizuhoMaintainsOutperform$30 → $42
18 Aug 2026HC Wainwright & Co.MaintainsBuy$34 → $55
18 Aug 2026HC Wainwright & Co.MaintainsBuy—
17 Aug 2026MizuhoMaintainsOutperform—
17 Aug 2026MizuhoMaintainsOutperform$24 → $30
3 Aug 2026CitigroupMaintainsBuy—
3 Aug 2026CitigroupMaintainsBuy$20 → $26
20 July 2026MizuhoMaintainsOutperform—
20 July 2026MizuhoMaintainsOutperform$21 → $24
25 June 2026GuggenheimMaintainsBuy$30 → $40

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

AMLX appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

AMLX vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 18 Nov 2026, Amylyx Pharmaceuticals, Inc. returned +90.8% against +12.2% for the S&P 500, dividends included.

AMLX vs S&P 500, last 12 monthsTotal return, rebased to 100
100150200250300Jan 26Apr 26Jul 26Oct 26AMLXS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

AMLX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
3
Analysts cutting
1
Fundamentals

Amylyx Pharmaceuticals, Inc. (AMLX) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
2.5×

Cheaper than 69% of US stocks

Price / sales
—
Price / book
4.7×

Cheaper than 19% of US stocks

EV / EBITDA
−17.8×

Cheaper than 90% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 33% of US stocks

Net margin
0.0%

Higher than 29% of US stocks

Returns & dividend
Return on equity
−30.1%

Higher than 27% of US stocks

Return on assets
−19.1%

Higher than 20% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Amylyx Pharmaceuticals, Inc. (AMLX) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Amylyx Pharmaceuticals, Inc. has a market value of $3.6B and an enterprise value of $3.1B.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$152.1M.

  • Diluted earnings per share, trailing twelve months: −$1.43.

  • Free cash flow in the twelve months to 30 June 2026: −$126.7M.

  • Shares outstanding: 111.4M.

  • Trailing P/E: 2.5×; forward P/E: −24.6× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Amylyx Pharmaceuticals, Inc. employs 136 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 17 Nov 2026

Data provided by Twelve Data

Peers

AMLX vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDrug Manufacturers - Specialty & Generic
CompanyMarket capTKN rank
AMLXAmylyx Pharmaceuticals, Inc.$3.6B60
XERSXeris Biopharma Holdings, Inc.$3.1B100
HIMSHims & Hers Health, Inc.$4.1B12
SUPNSupernus Pharmaceuticals, Inc.$2.4B—
LQDALiquidia Corp.$5.1B97
PBHPrestige Consumer Healthcare, Inc.$2.3B57
RGCRegencell Bioscience Holdings Ltd.$2.3B22

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Amylyx Pharmaceuticals, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest AMLX news & analysis

Amylyx Pharmaceuticals, Inc. (AMLX) Q3 2026 Earnings Call Transcript

Seeking Alpha · 6 Nov 2026neutral

Amylyx Pharmaceuticals held its Q3 2026 earnings call on November 5, 2026. The excerpt lists company executives and analysts who participated but provides no discussion of results or business updates.

Why it matters — The excerpt confirms the call took place, but includes no substantive information for AMLX watchers to assess.

Amylyx Pharmaceuticals Q3 Earnings Call Highlights

MarketBeat · 5 Nov 2026positive

Amylyx plans to seek U.S. approval by the end of 2026 for its experimental treatment for post-bariatric hypoglycemia. The company is preparing for a potential 2027 launch after positive late-stage trial results.

Why it matters — The update outlines Amylyx’s regulatory timeline and potential launch plans for the treatment.

Amylyx Pharmaceuticals Reports Third Quarter 2026 Financial Results

Business Wire · 5 Nov 2026neutral

Amylyx Pharmaceuticals announced that it reported its third-quarter 2026 financial results.

Why it matters — The item concerns the company's quarterly financial results, which may be relevant to AMLX watchers following its reported performance.

FAQ

Frequently asked questions about AMLX stock

What is the AMLX stock price forecast for 2026-2027?

The 11 Wall Street analysts covering Amylyx Pharmaceuticals, Inc. have a median 12-month price target of $40, with estimates ranging from $25 to $57. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is AMLX stock a buy right now?

Of the 11 analysts covering Amylyx Pharmaceuticals, Inc., 10 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Amylyx Pharmaceuticals, Inc. 60 out of 100 across roughly 4,600 US stocks as at 17 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank AMLX?

As at 17 Nov 2026, Amylyx Pharmaceuticals, Inc. ranks 60 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (94 of 100).

Will AMLX stock go up?

No one can know that. What the data says: the median 12-month target from 11 analysts implies +50.3% from the last close, and Ticker Nerd's factor model ranks Amylyx Pharmaceuticals, Inc. 60 out of 100 as at 17 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the AMLX stock forecast for 2030?

No analyst covering Amylyx Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for AMLX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $25 to $57 over the next 12 months.

How has AMLX stock performed over the past year?

Amylyx Pharmaceuticals, Inc. returned +90.8% over the 12 months to 18 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Amylyx Pharmaceuticals, Inc. do?

Amylyx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for diseases with significant unmet medical needs.

What is the latest news on AMLX?

The most recent item we track (Seeking Alpha, 15 Nov 2026): "Amylyx Pharmaceuticals, Inc. (AMLX) Discusses LUCIDITY Results and Avexitide Potential in Post-Bariatric Hypoglycemia Transcript". A Seeking Alpha transcript covers Amylyx Pharmaceuticals’ discussion of LUCIDITY results and avexitide’s potential in post-bariatric hypoglycemia.

Company

About Amylyx Pharmaceuticals, Inc.

Amylyx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for diseases with significant unmet medical needs. The company’s current pipeline centers on endocrine and neurodegenerative disorders, with avexitide as its lead investigational program. Avexitide is being studied as a first-in-class GLP-1 receptor antagonist for conditions linked to excessive insulin activity, including post-bariatric hypoglycemia and congenital hyperinsulinism. Amylyx also advances additional investigational therapies across other rare and serious diseases, reflecting a research portfolio built around well-defined biological targets and measurable clinical outcomes. Headquartered in Cambridge, Massachusetts, Amylyx Pharmaceuticals plays a role in the biotechnology market as a developer of targeted treatments for patients facing limited therapeutic options.

CEO Mr. Joshua B. Cohen · 136 employees · United States · https://amylyx.com